Cover image of the article: Experience With 68 Girls With Turner’s Syndrome and Evaluation of Final Height in 26 Patients Treated With Growth Hormone in Combination or Without Oxandrolone

Image Credit:Int J Endocrinol Metab

Experience With 68 Girls With Turner’s Syndrome and Evaluation of Final Height in 26 Patients Treated With Growth Hormone in Combination or Without Oxandrolone

Authors

H Moayeri1,*, GH Amir2
1Pediatrics Endocrine Department, Imam Khomeini Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2Pediatrics Endocrine Department, Imam Khomeini Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran,
*Corresponding Author: Pediatrics Endocrine Department, Imam Khomeini Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Email: hmoayeri@softhom.net

International Journal of Endocrinology and Metabolism:Vol. 3, issue 4; e94589
Published online:Dec 31, 2005
Article type:Research Article
Received:May 28, 2019
Accepted:Dec 31, 2005
How to Cite:Moayeri H, Amir G. Experience With 68 Girls With Turner’s Syndrome and Evaluation of Final Height in 26 Patients Treated With Growth Hormone in Combination or Without Oxandrolone. Int J Endocrinol Metab. 2005;3(4):e94589. doi:

Abstract

Short stature is a common feature in Turner’s syndrome; (TS) final height in untreated patients is on average 20cm below the population mean for adult women. When recombinant growth hormone (GH) became available, supraphysiologic GH doses with or without oxandrolone (OX) were administrated in order to improve growth in patients wih TS in several studies Objective: The objective of this study was to find out whether moderate doses of growth hormone in combination with oxandrolone and late initiation of puberty could improve adult height even in TS patients with late diagnosis. Materials and Methods: In this study the data an 68 patients with TS will be reported. Thirtythree patients with chronological age 17 years or above did not receive treatment. Thirty- five patients with TS were randomly assigned to receive either GH alone (0.375 mg/kg/week) by daily S.C injections (Group GH, n = 23) or in combination with OX 6 mg/kg/day P.O (group GH + OX, n = 12). Mean age at the onset of treatment was 10.7 years (GH) and 10.3 years (GH+OX), mean projected adult height (PAH) was 142.1 cm (GH) and 141.5 cm (GH+ ox). Puberty was induced at a mean age of 14.5 years. Results: There was a marked difference in group GH ± OX cumulative growth during 4.3 years of therapy in comparison with untreated TS patients. Twenty-six patients are now near or at final height: Group GH (n=17), mean final height was 148.7 cm (PAH 142.1 cm, gain 6.6 cm); group GH+ OX (n = 9), 151.9 cm (PAH, 141.5 cm, gain 9.4 cm). In the untreated group (n = 33), mean final height was 139.1 cm. Cumulative growth was more significant in GH plus OX than GH alone treated subjects (P<0.001). Conclusion: The diagnosis of TS is often delayed in our country and this defers the timely and appropriate treatment of short stature. Our results are in keeping with studies demonstrating moderate doses of GH plus OX and late induction of puberty are able to improve final height even in patients with TS, treated relatively late.

Highlights

Fulltext

This part is available in the PDF file.

References

  • 1.
    The references are available in the PDF file.

Copyright

© 2005, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

1
Jan
2004
Body Mass Index in Turner Syndrome Before and After Growth Hormone Therapy

Body Mass Index in Turner Syndrome Before and After Growth Hormone Therapy

Vakili R

R V. Body Mass Index in Turner Syndrome Before and After Growth Hormone Therapy. Int J Endocrinol Metab. 2004;2(2):. doi:

16
May
2014
Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly Progressive Puberty

Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly Progressive Puberty

Zohreh Karamizadeh,
Anis Amirhakimi,
Gholamhossein Amirhakimi

Karamizadeh Z, Amirhakimi A, Amirhakimi G. Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly Progressive Puberty. Inn J Pediatr. 2014;24(3):. doi:

7
Mar
2017
Testosterone Therapy Improves the First Year Height Velocity in Adolescent Boys with Constitutional Delay of Growth and Puberty

Testosterone Therapy Improves the First Year Height Velocity in Adolescent Boys with Constitutional Delay of Growth and Puberty

Dinesh Giri,
Prashant Patil,
Joanne Blair,
Poonam Dharmaraj,
Renuka Ramakrishnan,
Urmi Das
,et al.

Giri D, Patil P, Blair J, Dharmaraj P, Ramakrishnan R, et al. Testosterone Therapy Improves the First Year Height Velocity in Adolescent Boys with Constitutional Delay of Growth and Puberty. Int J Endocrinol Metab. 2017;15(2):e42311. doi: https://doi.org/10.5812/ijem.42311

23
Oct
2020
Effect of Growth Hormone Therapy in Patients with Noonan Syndrome: A Retrospective Study

Effect of Growth Hormone Therapy in Patients with Noonan Syndrome: A Retrospective Study

Louise Jayne Apperley,
Renuka Ramakrishnan,
Poonam Dharmaraj,
Urmi Das,
Mohammed Didi,
Jo Blair
,et al.

Apperley LJ, Ramakrishnan R, Dharmaraj P, Das U, Didi M, et al. Effect of Growth Hormone Therapy in Patients with Noonan Syndrome: A Retrospective Study. Int J Endocrinol Metab. 2020;18(4):e107292. doi: https://doi.org/10.5812/ijem.107292

30
Jun
2003
Current State of Growth Hormone Therapy

Current State of Growth Hormone Therapy

S Mohammadian,
A Sadeghi-Nejad

Mohammadian S, Sadeghi-Nejad A. Current State of Growth Hormone Therapy. Int J Endocrinol Metab. 2003;1(2):e94490. doi:

More by these authors

H MoayeriPubMedScholar
Share
Cited by
Metrics